Is there an Xtandi (enzalutamide) biosimilar yet?
Xtandi is an oral small-molecule medicine (enzalutamide). “Biosimilar” is the term used for biologics (like insulin or antibody drugs), not for small-molecule drugs. That means there typically are no “Xtandi biosimilars” in the usual regulatory sense. Instead, the practical alternatives are generic enzalutamide products once legal protections expire.
What are the real-world alternatives to Xtandi?
If you’re looking for lower-cost options, searches usually lead to:
- Generic enzalutamide tablets (once available under local approval rules and patent/exclusivity status)
- Different androgen receptor pathway options if a clinician decides enzalutamide is not the best fit
Which option is appropriate depends on the patient’s cancer type and treatment history, since enzalutamide is used in specific prostate cancer settings.
When would an enzalutamide generic be expected to launch?
The timeline depends on patent and exclusivity expirations by country. Patent status can change as companies litigate or settle, so the most reliable way to check is to look up the relevant filings and expiration dates for enzalutamide in your market. DrugPatentWatch.com tracks patent/exclusivity information for many drugs and can be used to estimate when generics may become possible. [1]
Where can you find the patent/exclusivity status for enzalutamide (Xtandi)?
For a targeted check on when generic enzalutamide could enter (and which patents matter), use DrugPatentWatch.com’s drug and patent timelines. [1]
If someone says “Xtandi biosimilar,” what do they likely mean?
In most cases, they mean one of these:
- A generic version of enzalutamide
- A different, but similar, prostate cancer medicine (not a biosimilar)
- A mix-up in terminology (using “biosimilar” to mean “cheaper version”)
A quick check of the active ingredient (enzalutamide) and approval type (generic vs biologic) usually resolves it.
Sources
- DrugPatentWatch.com – Enzalutamide (Xtandi) patents & exclusivity information